Compare Medtronic PLC (MDT) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Millicom International Cellular S.A. Common Stock — how do they compare? Medtronic PLC trades at $95.42 (market cap $120.53B), while Millicom International Cellular S.A. Common Stock trades at $81.07 (market cap $13.49B). The key difference: Medtronic PLC is far larger — about 8.9× Millicom International Cellular S.A. Common Stock's market cap, and Millicom International Cellular S.A. Common Stock pays the higher dividend (3.73%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| MDT | TIGO | |
|---|---|---|
Market Cap | $120.53B | $13.49B |
Volume | 49,858,758 | 1,314,537 |
Sector | Health | Media |
52-Week High | $105.35 | $104.31 |
52-Week Low | $73.75 | $45.81 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $139.87B | $24.53B |
Dividend Yield | 3.06% | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $93.01, up 1.17% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, 7% revenue growth in Q1 2026, and a 49-year dividend growth streak. Valuation metrics include a P/E of 22.91 and P/S of 3.19. Recent positive news includes FDA clearances for medical devices and raised full-year guidance, supporting investor confidence.
Outlook remains positive with analyst consensus at Buy (61%) and $97.73 price target. Key opportunities include sustained dividend growth and new product approvals, while risks involve debt increase to 31.11% of assets and competitive pressures. The stock's current level near resistance at $93 suggests potential for breakout if earnings momentum continues.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
